TRHC’S DoseMe® to Provide Precision Dosing Services for St. Joseph’s/Candler
November 13 2019 - 8:00AM
Tabula Rasa HealthCare® (NASDAQ:
TRHC), a healthcare technology company advancing the
field of medication safety, expands its hospital service footprint
through subsidiary company DoseMe’s strategic partnership with St.
Joseph’s/Candler, the premier not-for-profit health provider in
Savannah, GA. DoseMe will provide precision dosing services across
the provider’s specialized inpatient and outpatient hospitals. St.
Joseph’s/Candler is the first health system in Georgia to partner
with DoseMe and the 140th site across the United States,
Europe, Africa, and the Asia Pacific.
With the deployment of DoseMe’s web-based dose optimization
solution, DoseMeRx℠, St. Joseph’s/Candler will transition to an
AUC-based vancomycin dosing strategy. The move is prompted by the
revised therapeutic monitoring guidelines of vancomycin by Rybak et
al for the American Society of Health-System Pharmacists, the
Infectious Diseases Society of America, the Pediatric Infectious
Diseases Society and the Society of Infectious Disease
Pharmacists.
“At St. Joseph’s/Candler, we are always looking to provide the
best outcomes for our patients by using evidence-based approaches,”
states St. Joseph’s/Candler Clinical Pharmacist in Internal
Medicine Dustin Orvin, PharmD. “DoseMe’s Bayesian dosing platform
will make it easy and cost-effective for our pharmacists to apply
the new national dosing recommendations for vancomycin. We foresee
huge benefits for our patients in the seamless application of AUC
dosing and performance analysis, ensuring our patients are getting
the best outcome possible.”
DoseMeRx is a unique platform that uses Bayesian dosing to
calculate a precise dose to achieve a clinical target. The first in
the world to develop precision dosing software for clinical
practice, DoseMe’s solutions help to optimize dosing and streamline
operations, reduce adverse drug events and decrease costs.
“The expansion of DoseMe into another US hospital further
demonstrates the value DoseMeRx provides hospitals looking for
best-practice standardization,” said TRHC Chairman and CEO Calvin.
H. Knowlton, PhD. “The platform enables safer dosing techniques,
improving quality and outcomes. It creates more efficient workflows
and generates significant savings for our customers.”
“We’re delighted St Joseph’s/Candler has recognized not only the
clinical benefits of DoseMeRx, but also its workflow efficiencies
and mechanisms for facilitating the transition to AUC-based
vancomycin dosing,” says DoseMe CEO Charles Cornish.
About Tabula Rasa HealthCareTabula Rasa
HealthCare® (NASDAQ:TRHC) is a leader in providing
patient-specific, data-driven technology and solutions that enable
healthcare organizations to optimize performance to improve patient
outcomes, reduce hospitalizations, lower healthcare costs and
manage risk. Medication risk management is TRHC’s lead
offering, and its cloud-based software applications, including
EireneRx® and MedWise™, provide solutions for a range of payers,
providers and other healthcare organizations. For more information,
please visit www.tabularasahealthcare.com.
About DoseMeDoseMe® is a Tabula Rasa HealthCare
Company (NASDAQ: TRHC) and is the first company in the world to
develop precision dosing software - DoseMeRx℠ - developed
specifically for clinical practice. DoseMe's clinical decision
support solutions empower healthcare providers to optimize dosing
of high-risk parenteral medications to streamline operations,
reduce adverse drugs events, decrease costs and improve patient
outcomes. For more information, visit doseme-rx.com
About St Joseph’s/CandlerSt. Joseph’s/Candler
is a 714-bed, Magnet-designated health system for nursing
excellence, with a focus on the latest technologies and research.
It is anchored by St. Joseph’s Hospital and Candler Hospital. Its
comprehensive network includes centers of excellence for oncology,
cardiovascular, neurosciences, women’s and children’s services,
orthopedics, pulmonary medicine and a variety of other disease
specialties. SJ/C's Nancy N. and J.C. Lewis Cancer & Research
Pavilion has been selected to be part of the National Cancer
Institute’s Community Oncology Research Program. St.
Joseph’s/Candler is a not-for-profit health system serving 33
counties in southeast Georgia and three in the South Carolina Low
Country and is the largest and only faith-based institution in the
region. For more information, visit www.sjchs.org.
Forward-Looking StatementsThis press release
includes forward-looking statements that we believe to be
reasonable as of today’s date, including statements regarding
Medication Risk Mitigation technology. Such statements are
identified by use of the words “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,”
“should,” and similar expressions. These forward-looking
statements are based on management’s expectations and assumptions
as of the date of this press release. Actual results might
differ materially from those explicit or implicit in the
forward-looking statements. Important factors that could cause
actual results to differ materially include: the need to innovate
and provide useful products and services; risks related to changing
healthcare and other applicable regulations; increasing
consolidation in the healthcare industry; managing our growth
effectively; our ability to adequately protect our intellectual
property; and the other risk factors set forth from time to time in
our filings with the SEC, including those factors discussed
under the caption “Risk Factors” in our most recent annual report
on Form 10-K, filed with the SEC on March 1, 2019, and in
subsequent reports filed with or furnished to the SEC, copies of
which are available free of charge within the Investor Relations
section of the TRHC website http://ir.trhc.com or upon request from
our Investor Relations Department. Any forward-looking statement
speaks only as of the date on which it was made. TRHC assumes no
obligation and does not intend to update these forward-looking
statements, except as required by law, to reflect events or
circumstances occurring after today’s date.
Media Contact:Dianne Semingsondsemingson@trhc.comT: (215)
870-0829 |
Investors: Bob East or Asher Dewhurst Westwicke Partners
tabularasa@westwicke.comT: (443) 213-0500 |
Tabula Rasa HealthCare (NASDAQ:TRHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tabula Rasa HealthCare (NASDAQ:TRHC)
Historical Stock Chart
From Apr 2023 to Apr 2024